Fate Therapeutics– tag –
-
BioInformant Report Outlines 2026 iPSC-Derived Cell Therapeutic Pipeline, Highlighting Safety Challenges and Key Developers
BioInformant USA Overview This article provides an overview of a market research report by BioInformant, focusing on the 2026 pipeline for iPSC-derived cell therapeutics. The report analyzes the current state and future challenges, ident... -
Fate Therapeutics to Detail iPSC-Derived Cellular Immunotherapy Pipeline at Cantor Global Healthcare Conference
Fate Therapeutics Press Releases / Barchart.com USA Overview Fate Therapeutics announced its management will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, September 9-12, 2026. The company plans t... -
Fate Therapeutics to Present Encore Clinical Data for iPSC-Derived FT819 in Systemic Scleroderma
Fate Therapeutics, Inc. Investors USA Overview Fate Therapeutics will re-present clinical data for FT819, its iPSC-derived, off-the-shelf CAR T-cell product candidate, at the CCR – West 2026 conference. The data potentially shows early c... -
Fate Therapeutics to Announce iPSC-Derived Immunocellular Therapy Strategy at 2026 Cantor Conference
GlobeNewswire USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. The company holds a leading position in creating multi-gene-edited iPSC lines and manufac... -
Fate Therapeutics to Present on iPSC-Derived CAR T Cell Candidate FT819 for Autoimmune Diseases at 2026 Cantor Global Healthcare Conference
Stock Titan USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 9th, where it will discuss its off-the-shelf iPSC-derived CAR T cell candidate FT819 f... -
Fate Therapeutics Initiates Phase 1/2 Trial for Novel Cell Therapy FT839 in Autoimmune Diseases, Expanding Pipeline
TipRanks.com USA Overview Fate Therapeutics has launched a Phase 1/2 dose-escalation and expansion trial for its novel cell therapy candidate, FT839, in patients with autoimmune diseases. This intravenously administered therapy is design... -
Fate Therapeutics Initiates Phase 2 RECLAIM-LN Trial for Lupus Nephritis with Off-the-Shelf iPSC-Derived CD19 CAR-T Cell Therapy FT819
Seeking Alpha USA Overview Fate Therapeutics has commenced its Phase 2 RECLAIM-LN trial for lupus nephritis, administering the first patient with its iPSC-derived CD19 CAR-T cell therapy, FT819, in an outpatient setting. This marks a sig... -
Next-Generation Bioinks Create New Opportunities in Tissue Engineering and Drug Discovery via 3D Bioprinting
ACS Publications USA Overview Advances in next-generation bioinks are significantly propelling the fields of tissue engineering and regenerative medicine through 3D bioprinting technology. These bioinks are essential for creating microen... -
Penn State Team Establishes Foundation for 3D Bioprinted Spheroids to Promote Bone Tissue Regeneration and Vascularization
Penn State News USA Overview An interdisciplinary team at Penn State University has laid the groundwork for 3D printing spheroids, small living cell clusters, capable of regenerating bone tissue following severe trauma or infection. Rese... -
DelveInsight Report: Over 12 Companies Enter iPSC-Derived NK Cell Therapy Pipeline, Led by Century Therapeutics and Fate Therapeutics
openPR.com (DelveInsight) India Overview This article provides an overview of a market research report published by DelveInsight, highlighting the rapid growth in the iPSC-derived NK cell therapy pipeline, with over 12 companies developi...
